Adaptive Biotechnologies

Shares of Adaptive Biotechnologies rose to a new 52-week high of $26.63, delivering a year-to-date return of 101.7%. Market capitalization stands at $4.18 billion, while an analysis by InvestingPro points to possible overvaluation. For Q2 the company reported an adjusted loss of $0.25 per share (expectation: -$0.14) on revenue of $71.6 million (expectation: $65.8 million, +22% year/year). Core MRD business grew 49% year-over-year excluding milestone payments, clonoSEQ volume rose 43%; BTIG and Guggenheim raised their price targets to $25 and each reiterated "Buy". » More on de.investing.com

Adaptive Biotechnologies' stock rose to a 52-week high of $25.04, about 104% above its level a year ago; market capitalization is roughly $3.95 billion. The company reported 50% revenue growth over the past 12 months and Q2 revenue of $71.6 million (+22% y/y), but missed consensus with an adjusted loss of $0.25 per share. BTIG and Guggenheim raised their price targets to $25 and both reiterated a "Buy" rating, citing strong volume growth for the clonoSEQ MRD test. An analysis currently values the stock above its fair value, so investors should weigh valuation against momentum. » More on de.investing.com

Adaptive Biotechnologies shares rose to a new 52-week high of $23.25 and are currently trading just below that at $23.10. The stock has a year-to-date performance of 120.31%; the company has a market capitalization of $3.57 billion and reported revenue growth of 56% over the past twelve months. Q2 results were mixed: adjusted loss of $0.25 per share (expectation -$0.14) on revenue of $71.6 million (expectation $65.8 million) and a 43% volume increase in the clonoSEQ test. InvestingPro rates the stock as rather overvalued and warns of high volatility, while BTIG and Guggenheim raised their price targets to $25 and maintain buy recommendations. » More on de.investing.com